Editas up on agreement with Vertex Pharma for gene editing tech

Editas Medicine

13/12/2023 15:08

** Shares of gene editing co Editas Medicine  EDIT.O  up
4.2% to $10.3
    ** Co and Vertex Pharmaceuticals  VRTX.O  enter into a
license agreement for VRTX to obtain a non-exclusive license for
EDIT's gene editing technology  
    ** EDIT's gene editing tech, Cas9,  provides access to a
broad range of genetic mutations, delivering a precise and
targeted approach to gene editing medicines
    ** ** Cas9's use will be for medicines, including Casgevy -
Vertex and partner CRISPR Therapeutics  CRSP.BN  gene therapy,
that target a gene known as BCL11A
    ** Casgevy got approval from the U.S. FDA last week for
treating sickle cell disease (SCD) - a painful, inherited blood
disorder
    ** The agreement extends EDIT's cash runway into 2026 
    ** YTD, EDIT stock up 15.6%

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))